Search Results

You are looking at 1 - 10 of 327 items for :

  • "generalizability" x
  • Refine by Access: All x
Clear All
Full access

Laura J. Libby, Navneet Narula, Helen Fernandes, James F. Gruden, David J. Wolf, and Daniel M. Libby

Background Lymphangiomatosis (eg, generalized lymphatic anomaly [GLA]) is an abnormal proliferation of lymphatic endothelial cells. In 2014, the International Society for the Study of Vascular Anomalies (ISSVA) omitted the terms “lymphangioma

Full access

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

broader subset of patients. This section discusses insights highlighting relative limitations to the broad generalizability of the adjuvant RT trial data and recent data outlining current understanding of how to optimize the delivery of salvage RT when the

Full access

Jason Hu, Armen G. Aprikian, Marie Vanhuyse, and Alice Dragomir

period. Two additional models were fitted for the secondary outcomes of baseline and follow-up BMD testing. Multivariable analyses were conducted using generalized linear mixed models with a logit link, and a binary distribution for the dependent variable

Full access

The Cancer Center Cessation Initiative Implementation Science Working Group

. Illustrative example of impact from C3I-supported efforts on reach from Washington University in St. Louis. Note: Relative risk (adjusted for age, sex, race), 10.06 (95% CI, 6.89–14.68); P <.0001 in generalized estimating equation models. Cohort 2

Full access

Joseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, Timothy A. Lin, Austin B. Miller, Amit Jethanandani, Andres F. Espinoza, Dario Pasalic, Vivek Verma, Noam A. VanderWalde, Benjamin D. Smith, Grace L. Smith, C. David Fuller, Prajnan Das, Bruce D. Minsky, Claus Rödel, Emmanouil Fokas, Reshma Jagsi, Charles R. Thomas Jr, Ishwaria M. Subbiah, Cullen M. Taniguchi, and Ethan B. Ludmir

may influence trial results and subsequent FDA drug approvals. 12 Similar practices may have important implications for the generalizability of trial findings, because a considerable proportion of patients with cancer do not present at diagnosis with

Full access

Zhi Ven Fong and Cristina R. Ferrone

Borderline and Locally Advanced PDAC Given this change in effective systemic therapy for patients with locally advanced PDAC, the pool of patients eligible for resection with curative intent has greatly expanded. However, the generalizability of present

Full access

Narendranath Epperla, Melissa Pavilack, Temitope Olufade, Richa Bashyal, Teng Huang, Huseyin Yuce, and Leslie Andritsos

occurrence of myelosuppression (MSPN) and opportunistic infections (OI) as these were highest incident and clinically important AEs observed. Generalized linear models were used to compare outcomes during the 12-month follow-up. Results: Of the 219 pts with

Full access

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty, and Barbara A. Goff

factors. The distribution of total cost was slightly right-skewed, indicating a potential violation to the normal distribution assumption of cost. In the multivariate adjusted analyses for cost, the general linear model, log-linear model, and generalized

Full access

Chizoba Nwankwo and Michael J. Doane

during the past 2 weeks), (3) anxiety severity via the Generalized Anxiety Disorder 7-Item Scale (GAD-7), and (4) healthcare resource use for mental health services (ie, visits to psychologists and psychiatrists during past 6 months). Results: Analyses

Full access

Andrew J Klink, Bruce Feinberg, Frank Xiaoqing Liu, Sama Ahsan, Damion Nero, and Bartosz Chmielowski

by logistic regressions, and adjusted costs were estimated by generalized linear models to control for differences in pt characteristics across groups. Results: Among 1,599 MM pts (255 PD-1, 555 CTLA-4, 88 CTLA-4+PD-1, 210 mono-TT, 102 combo-TT, 389